{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:18:55Z","timestamp":1783664335287,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40618-017-0772-1","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T05:51:18Z","timestamp":1508219478000},"page":"549-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution"],"prefix":"10.1007","volume":"41","author":[{"given":"F.","family":"Guaraldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"La Selva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Sam\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Arvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"772_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974\u20131982. doi:\n                        10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"key":"772_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. doi:\n                        10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"772_CR3","first-page":"1","volume":"3","author":"E Rossi","year":"2016","unstructured":"Rossi E, Sgambato A, De Chiara G, Ciardiello F, Gridelli C (2016) Thyroid-induced toxicity of check-point inhibitors immunotherapy in the treatment of advanced non-small cell lung cancer. J Endocrinol Diabetes 3:1\u201310","journal-title":"J Endocrinol Diabetes"},{"key":"772_CR4","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11:e0160221. doi:\n                        10.1371\/journal.pone.0160221","journal-title":"PLoS One"},{"key":"772_CR5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0712","author":"M Hazarika","year":"2017","unstructured":"Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, Zhao L, Welch J, Graham L, Libeg M, Sridhara R, Keegan P, Pazdur R (2017) US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. doi:\n                        10.1158\/1078-0432.CCR-16-0712\n                        \n                     (epub ahead of print)","journal-title":"Clin Cancer Res"},{"key":"772_CR6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432","author":"JA Beaver","year":"2017","unstructured":"Beaver JA, Theoret MR, Mushti S, He K, Libeg M, Goldberg K, Sridhara R, McKee AE, Keegan P, Pazdur R (2017) FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. doi:\n                        10.1158\/1078-0432\n                        \n                     (epub ahead of print)","journal-title":"Clin Cancer Res"},{"key":"772_CR7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:2092\u20132099. doi:\n                        10.1200\/JCO.2014.60.0379","journal-title":"J Clin Oncol"},{"key":"772_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2217\/fon.15.222","volume":"12","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O, El Halawani H, Fouad M (2016) Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol 12:413\u2013425. doi:\n                        10.2217\/fon.15.222","journal-title":"Future Oncol"},{"key":"772_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","volume":"28","author":"F Torino","year":"2016","unstructured":"Torino F, Corsello SM, Salvatori R (2016) Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28:278\u2013287. doi:\n                        10.1097\/CCO.0000000000000293","journal-title":"Curr Opin Oncol"},{"key":"772_CR10","volume-title":"AJCC cancer staging manual","author":"S Edge","year":"2010","unstructured":"Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, Heidelberg","edition":"7"},{"key":"772_CR11","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG, RECIST working group (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. doi:\n                        10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"772_CR12","doi-asserted-by":"publisher","first-page":"8910","DOI":"10.18632\/oncotarget.13315","volume":"8","author":"R Costa","year":"2017","unstructured":"Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ (2017) Toxicity profile of approved anti-PD1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 8:8910\u20138920. doi:\n                        10.18632\/oncotarget.13315","journal-title":"Oncotarget"},{"key":"772_CR13","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J Filette de","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101:4431\u20134439","journal-title":"J Clin Endocrinol Metab"},{"key":"772_CR14","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryderl M (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102:2770\u20132780","journal-title":"J Clin Endocrinol Metab"},{"key":"772_CR15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","volume":"18","author":"JR Garber","year":"2012","unstructured":"Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 18:988\u20131028","journal-title":"Endocr Pract"},{"key":"772_CR16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016) 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343\u20131421","journal-title":"Thyroid"},{"key":"772_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves\u2019 disease: frequently asked questions and answers (if any). J Endocrinol Invest 39:1105\u20131114. doi:\n                        10.1007\/s40618-016-0505-x","journal-title":"J Endocrinol Invest"},{"key":"772_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0042-119528","volume":"125","author":"M Alhusseini","year":"2017","unstructured":"Alhusseini M, Samantray J (2017) Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Exp Clin Endocrinol Diabetes 125:267\u2013269. doi:\n                        10.1055\/s-0042-119528","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"772_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/978-3-642-30726-3_17","volume":"214","author":"A Gessl","year":"2012","unstructured":"Gessl A, Lemmens-Gruber R, Kautzky-Willer A (2012) Thyroid disorders. Handb Exp Pharmacol 214:361\u2013386. doi:\n                        10.1007\/978-3-642-30726-3_17","journal-title":"Handb Exp Pharmacol"},{"key":"772_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13:195\u2013207. doi:\n                        10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"772_CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709\u2013718","journal-title":"N Engl J Med"},{"key":"772_CR22","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mayroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043\u20136053","journal-title":"J Clin Oncol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0772-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0772-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0772-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T07:25:38Z","timestamp":1523863538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0772-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0772-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}